TABLE III.
Characteristics of economic abstracts reviewed
| Variable | Frequency | Percentage |
|---|---|---|
| Meeting type | ||
| asco | 114 | 53 |
| ash | 31 | 14 |
| ispor | 71 | 33 |
| Meeting year | ||
| 1997 | 8 | 3.7 |
| 1998 | 3 | 1.4 |
| 1999 | 6 | 2.8 |
| 2000 | 11 | 5.1 |
| 2001 | 11 | 5.1 |
| 2002 | 7 | 3.2 |
| 2003 | 7 | 3.2 |
| 2004 | 15 | 6.9 |
| 2005 | 17 | 7.9 |
| 2006 | 26 | 12.0 |
| 2007 | 38 | 17.6 |
| 2008 | 30 | 13.9 |
| 2009 | 37 | 17.1 |
| Study location | ||
| Europe | 57 | 26 |
| North America | 136 | 63 |
| Missing | 10 | 4.6 |
| Other | 13 | 6.0 |
| Cancer site | ||
| Breast | 66 | 31 |
| Gastrointestinal | 31 | 14 |
| Genitourinary | 30 | 14 |
| Gynecologic | 5 | 2.3 |
| Hematologic | 43 | 20 |
| Lung | 17 | 7.9 |
| Other | 24 | 11 |
| Type of analysis | ||
| cea | 81 | 38 |
| cma | 3 | 1.4 |
| cua | 104 | 48 |
| Missing | 28 | 13 |
asco = American Society of Clinical Oncology; ash = American Society of Hematology; ispor = International Society for Pharmacoeconomics and Outcomes Research; cea = cost-effectiveness analysis; cma = cost-minimization analysis; cua = cost–utility analysis.